HOUSTON--(BUSINESS WIRE)--CytoGenix, Inc. (OTCBB:CYGX) announced today that it has executed a Letter of Intent regarding synDNA™ development with Eurogentec S.A. The Companies have identified an area of mutual interest regarding development of synDNA™ and will collaborate to optimize manufacturing and to implement purification and quality control parameters. A successful collaboration will facilitate submission of European Union (EU) regulatory filings with products containing synDNA™.
